Is MASLD Not Just a Liver Disease? Bidirectional Gut–Liver Crosstalk as a Driver of Chronic Liver Disease
Life · 27.06.2026 · 16 (7) · 1076
DOI: 10.3390/life16071076 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 27.06.2026. Verfasst von Iulia Cristina Marginean und 6 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Irritable bowel syndrome (IBS) and metabolic dysfunction-associated steatotic liver disease (MASLD) are two of the most common gastroenterological conditions worldwide. Traditionally viewed as unrelated, with one serving a canonical functional role and the other a purely metabolic function, these two processes have recently been linked by compelling evidence, challenging their traditional segregation and pointing to a significant, biologically relevant association. This review aims to evaluate the current evidence for a potential causal contribution of IBS to hepatic steatosis, critically examining the proposed pathophysiological mechanisms via the gut–liver axis while acknowledging that the available data are primarily observational. Notably, epidemiological studies demonstrate a 1.4–2.0-fold increased association between IBS and MASLD, independent of obesity and metabolic syndrome, though causality remains to be established. The primary mechanism is increased intestinal permeability (“leaky gut”) leading to endotoxemia, activation of hepatic toll-like receptor 4 (TLR4) receptors, and subsequent de novo lipogenesis. The relationship is bidirectional, with steatosis also worsening gut barrier function. Therefore, we highlight emerging evidence suggesting that irritable bowel syndrome, particularly the diarrhea-predominant subtype (IBS-D), may contribute to hepatic steatosis through plausible biological mechanisms, though direct causal evidence in humans remains limited. Accordingly, routine screening for metabolic dysfunction-associated steatotic liver disease (MASLD) may be warranted in patients with long-standing IBS-D.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Endocrinology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Radiology and Medical Imaging, Clinical Emergency County Hospital Craiova, 200349 Craiova, Romania.
ORCID-Profile: Iulia Cristina Marginean, Sergiu Marian Cazacu, Cristina Maria Marginean, George Alexandru Iacob
Zitieren
APA
Marginean, I. C., Cazacu, S. M., Marginean, C. M., Popescu, M., Iacob, G. A., Popescu, M. S., & Vere, C. C. (2026). Is MASLD Not Just a Liver Disease? Bidirectional Gut–Liver Crosstalk as a Driver of Chronic Liver Disease. Life, 16(7), 1076. https://doi.org/10.3390/life16071076
Vancouver
Marginean IC, Cazacu SM, Marginean CM, Popescu M, Iacob GA, Popescu MS, et al. Is MASLD Not Just a Liver Disease? Bidirectional Gut–Liver Crosstalk as a Driver of Chronic Liver Disease. Life. 2026;16(7):1076. doi:10.3390/life16071076
BibTeX
@article{Marginean2026,
author = {Marginean, Iulia Cristina and Cazacu, Sergiu Marian and Marginean, Cristina Maria and Popescu, Mihaela and Iacob, George Alexandru and Popescu, Marian Sorin and Vere, Cristin Constantin},
title = {Is MASLD Not Just a Liver Disease? Bidirectional Gut–Liver Crosstalk as a Driver of Chronic Liver Disease},
journal = {Life},
year = {2026},
volume = {16},
number = {7},
pages = {1076},
doi = {10.3390/life16071076}
}
EUVIMED